When giving single agent docetaxel for patients with metastatic NSCLC who have progressed on platinum and immunotherapy, do you stop after 6 cycles or do you continue as long as tolerated and disease is stable?   

When giving docetaxel to patients with NSCLC who have disease progression after platinum chemotherapy and immunotherapy, I typically give it in combination with ramucirumab per the REVEL study (Garon et al., PMID 24933332). In this study, patients with NSCLC who had disease progression after platinu...